Insulet Corporation (NASDAQ: PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls.
BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp....
Insulet (NASDAQ: PODD) releases its next round of earnings Wednesday. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
Earnings and Revenue
Insulet's per-share loss will be near 8 cents on sales...
Raymond James identified four major tailwinds for Insulet Corporation (NASDAQ: PODD) that the firm said could help drive 20-percent-plus revenue growth over the next two years.
Raymond James analyst Jayson Bedford upgraded...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Insulet (PODD):
Insulet (PODD) is competing against Mini Med, a division of Medtronic, for the insulin delivery system segment. The product has a needle which is inserted until an audible sound is heard, then the needle withdraws leaving behind a tethlon tube. Insuline is dripped from the pod into the body via the tube. When the pod is low on the solution, more is added. This avoids the nasty needle sticks many diabetics loath.
The pod can be worn many places on the body and has no major tubes of complicated computer readouts, vs. the typical insulin pump.
Often a physician asks the patient to try wearing the pod while it drips saline. Uptake is high afterwards as the pod is so comfortable.
Per the CEO, Duane Desisto, they may have a pump company burried in a pod company. Meaning that other drugs may be delivered via the pod.